DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
76	下垂体性ゴナドトロピン分泌亢進症	1

告示番号

疾患名（ページ内リンク）

臨床試験数

下垂体性ゴナドトロピン分泌亢進症

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00635817 (ClinicalTrials.gov)	June 2008	7/3/2008	A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty	A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty	Puberty, Precocious	Drug: Leuprolide acetate 11.25 mg;Drug: Leuprolide acetate 30 mg	Abbott	NULL	Completed	2 Years	11 Years	All	84	Phase 3	United States;Puerto Rico

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00635817
(ClinicalTrials.gov)

June 2008

7/3/2008

A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty

A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty

Puberty, Precocious

Drug: Leuprolide acetate 11.25 mg;Drug: Leuprolide acetate 30 mg

Abbott

NULL

Completed

2 Years

11 Years

All

Phase 3

United States;Puerto Rico